Clinical trials: Pyoderma
Pyoderma Gangrenosum
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers.
- Trial name
- NCT06624670
- Testing
- Spesolimab, Prednisone, Prednisolone
- Where
- 104 sites in United States, Argentina and 19 more
- Volunteers
- 90 people
- Sponsor
- LEO Pharma
Pyoderma Gangrenosum
Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum
This is a single-center, open-label, single-arm pilot study evaluating topical ruxolitinib (OPZELURA) as a treatment for adults with Pyoderma Gangrenosum (PG), a chronic inflammatory skin condition that causes painful ulcers.
- Trial name
- TRIUMPH (NCT07783412)
- Testing
- topical ruxolitinib 1.5% cream
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Oregon Health and Science University
Pyoderma Gangrenosum, Skin Diseases
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma
- Trial name
- GEORGE (NCT06563323)
- Testing
- Guselkumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oregon Health and Science University
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Pyoderma Gangrenosum
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
This study was designed to assess the therapeutic efficacy and safety of SHR-1139 Injection in adult patients with ulcerative pyoderma gangrenosum.
- Trial name
- NCT07337564
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shandong First Medical University
Pyoderma Gangrenosum
Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum
The purpose of the study is to learn more about an experimental drug bimekizumab that may be helpful for Pyoderma Gangrenosum (PG). Bimekizumab will be referred to as the study drug throughout this form.
- Trial name
- BEAT-PG (NCT07767864)
- Testing
- Bimekizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oregon Health and Science University
Pyoderma Gangrenosum
Spesolimab in Pyoderma Gangrenosum
The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma gangrenosum.
- Trial name
- NCT06092216
- Testing
- Spesolimab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pyoderma Gangrenosum
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.
- Trial name
- NCT07444684
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pyoderma Gangrenosum
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
- Trial name
- NCT05964413
- Testing
- vilobelimab
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 54 people
- Sponsor
- InflaRx GmbH
Pyoderma Gangrenosum
A Novel Therapeutic Treatment of Pyoderma Gangrenosum
Pyoderma gangrenosum is a chronic debilitating ulcerative neutrophilic condition usually affecting the skin. The pathogenesis of pyoderma gangrenosum is poorly understood.
- Trial name
- NCT05120726
- Testing
- Dehydrated human amnion/chorion membrane
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Pyoderma Gangrenosum
Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
Pyoderma gangrenosum (PG) is a chronic inflammatory condition with severe painful ulcers. We hypothesize that Platelet-rich plasma(PRP) therapy derived from patient's own blood has a high concentration of endogenous growth…
- Trial name
- NCT05984654
- Testing
- Platelet rich plasma therapy
- Where
- United States
- Sponsor
- Ohio State University
Pyoderma Gangrenosum
A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
Pyoderma Gangrenosum (PG) is a rapidly progressive disease and presents as painful, single or multiple lesions, with several clinical variants, in different locations, with a nonspecific histology, which makes the diagnosis…
- Trial name
- NCT04750213
- Where
- 46 sites in Japan
- Volunteers
- 60 people
- Sponsor
- AbbVie
Diabetic Foot, Pressure Ulcer
A Real-World Registry of Chronic Wounds and Ulcers
WOUNDJOURNEY is a longitudinal, real-world, observational registry designed to capture the full clinical course and patient journey associated with chronic wounds and ulcers.
- Conditions
- Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis
- Trial name
- WOUNDJOURNEY (NCT02280733)
- Testing
- Usual care
- Where
- United States
- Volunteers
- 300,000 people
- Sponsor
- U.S. Wound Registry
Pyoderma Gangrenosum
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.
- Trial name
- NCT01965613
- Testing
- Xilonix
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Pyoderma Gangrenosum
Deucravacitinib in PG
The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).
- Trial name
- NCT05821374
- Testing
- Deucravacitinib
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Pyoderma Gangrenosum, Skin Diseases
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum
- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma
- Trial name
- NCT04901325
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oregon Health and Science University
Pyoderma Gangrenosum
Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum
Rationale: Pyoderma gangrenosum (PG) is a rare auto-inflammatory neutrophilic dermatosis characterized by a spectrum of clinical presentations with variable courses. Diagnosis and management are challenging in PG.
- Trial name
- HOTPANTS (NCT05343754)
- Testing
- Hyperbaric oxygen, Control group
- Where
- Netherlands
- Volunteers
- 3 people
- Sponsor
- Erasmus Medical Center
Pyoderma Gangrenosum
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
- Trial name
- NCT03137160
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Pyoderma
Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma
The study is aimed to: evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma, evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared…
- Trial name
- NCT05561816
- Testing
- Hydroxymethylquinoxalindioxyde, Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
- Where
- 10 sites in Russia
- Volunteers
- 240 people
- Sponsor
- Valenta Pharm JSC
Pyoderma Gangrenosum
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.
- Trial name
- NCT03971643
- Testing
- vilobelimab
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 19 people
- Sponsor
- InflaRx GmbH